To evaluate the effect of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) on clinical and economic outcomes in patients with type 2 diabetes (T2D).
metformin monotherapy, through dual and/or triple therapies, to combination injectable therapy. Guidelines note that initial combination therapy using metformin plus a second agent may be better than sequential therapy, allowing patients to more rapidly achieve glycated haemoglobin (HbA1c) targets. 1, 2 This approach is suggested to be appropriate for patients with more elevated HbA1c levels (eg, ≥9.0%) who are considered unlikely to achieve glycaemic targets using metformin monotherapy.
When injectable therapy is appropriate, the latest ADA guidelines recommend starting with a basal insulin replacement and, if needed, intensifying treatment by adding either a prandial insulin, a glucagonlike peptide-1 receptor agonist (GLP-1 RA), or switching to a premixed insulin. 2 The latest AACE/ACE guidelines also recommend starting with basal insulin and intensifying, if needed, with either prandial insulin or a GLP-1 RA, a sodium glucose co-transporter 2 -(SGLT2) inhibitor, or a dipeptidyl peptidase-4 (DPP-4) inhibitor. 3 Recent studies have demonstrated the effectiveness of combining a GLP-1 RA (either shorter-or longer-acting weekly formulations) with basal insulin, where addition of a GLP-1 RA was associated with either equivalent or slightly better glycaemic control than that with the addition of prandial insulin, combined with weight loss and lower risk of hypoglycemia. [4] [5] [6] [7] Available data suggest that either a GLP-1 RA or prandial insulin may be appropriate, and that a GLP-1 RA might be a safer option. 6, 8, 9 For patients with T2D, there is evidence that early initiation of antihyperglycaemic therapy and prompt treatment intensification, when appropriate, reduce the risk of de novo or worsening micro-and macrovascular complications. 10 Additionally, timely initiation and intensification of treatment are more likely to result in the desired glycaemic control, whereas delaying therapy until HbA1c is elevated (the so called "treat-tofail" approach) predicts suboptimal response to treatment interventions. 11, 12 Despite guideline recommendations, only 52.5% of patients with T2D in the US reached a glycaemic target of HbA1c < 7.0% from 2007 to 2010. 13 Similarly, reports from around the world describe that glycaemic control (HbA1c <7.0%) was reported in 31.1% of urban and 30.8% of rural patients in India, 14 and in 39.7% of patients in China. 15 And, across 9 European countries (Belgium, France, Germany, Greece, Italy, Netherlands, Spain, Turkey, UK), 37.4% of patients had not achieved their glycaemic target of HbA1c < 7.0%. 16 Despite general awareness of the disconnect between recommended treatment targets and achievement in clinical practice, clinical inertia or the failure to intensify treatment in a timely manner when patients do not reach recommended glycaemic targets, remains a global problem. 17 Numerous studies have shown that multiple complex factors can act as barriers to treatment intensification and contribute to clinical inertia. These include: physician reluctance to prescribe injectable agents for patients with uncontrolled T2D despite the use of multiple OADs, 18 poor communication between physicians and patients, 17 rudimentary patient understanding of the importance of maintaining good glycaemic control and of the risks of complications associated with poor control, 17 patient resistance to treatment escalation related to fears concerning therapy or the implications of treatment intensification concerning disease progression, 19 poor self-management skills, 19 and discontinuation of injectable therapy because of patient concerns such as fear of needles and associated pain. 20 It has been suggested that clinical inertia is a factor that contributes to poor outcomes in patients with T2D, resulting in increased healthcare utilization and associated costs. 21, 22 The incentive to develop effective strategies to overcome clinical inertia and improve management of T2D will require a deeper understanding of the drivers of, and contributors to, clinical inertia, as well as the effects of clinical inertia on clinical outcomes and the economic burden resulting from delayed treatment intensification.
The objective of this study was to evaluate the effect of delaying treatment intensification with a GLP-1 RA on longitudinal change in clinical outcomes and economic burden in patients with T2D who are inadequately controlled with basal insulin.
| RESEARCH DESIGN AND METHODS

| Study design and eligibility criteria
We conducted a retrospective observational study using the IMPACT™ 
| Economic outcomes
Semi-annual healthcare costs (USD adjusted to the year 2011) were described at baseline for the 3 groups. Total healthcare costs consisted of claims-based actual costs captured from the IMPACT database.
These included total inpatient, outpatient, emergency department, and prescription drug costs. Changes in semi-annual total healthcare costs and diabetes-related costs from baseline to follow-up were evaluated.
| Statistical analyses
Descriptive statistics were reported for patients' demographic and baseline characteristics, while univariate group comparisons were conducted using χ 2 tests for categorical variables and 2-sample 3 | RESULTS
| Patient baseline demographics and clinical characteristics
Patient disposition is summarized in Figure 2 . Of the 1552 patients who were eligible for inclusion in the study, 139 (9.0%) met criteria for inclusion in the early intensification group, 588 (37.9%) met criteria for inclusion in the delayed intensification group, and 825 (53.2%) met criteria for inclusion in the no intensification group.
Patient baseline demographics and clinical characteristics are summarized in Table 1 . Mean HbA1c values were elevated at baseline in each of the groups (early intensification: 9.16%; delayed intensification:
9.07%; no intensification: 9.34%). Age, CCI score, diagnosis of obesity, number of OADs used, and total outpatient costs all differed significantly at baseline among the groups. Compared with the other groups, patients in the early intensification group were younger, had higher outpatient costs, had higher rates of hospitalization and endocrinology visits, were more likely to be obese, and were more likely to use a higher number of OADs during the baseline period. In the delayed intensification group, patients had a lower CCI score and a slightly lower mean HbA1c value. In the no intensification group, patients were older and more likely to use fewer OADs during the baseline period.
| Change in glycaemic control
At follow-up after 12 months, a significant reduction in HbA1c from baseline was seen in the intensification groups ( Figure 3 ). The least squares (LS) mean HbA1c reduction from baseline was significantly greater (P < .001) in the early intensification group (from 9.16% to 8.01%; decrease of 1.01%) than in the delayed intensification group (from 9.07% to 8.39%; decrease of 0.68%) and the no intensification group (from 9.32% to 9.12%; decrease of 0.20%). In the early and delayed intensification groups, the LS mean reduction in HbA1c was significantly greater (P < .001) than in the no intensification group.
| Change in hypoglycaemia rate
The rates of hypoglycaemic events per PYE according to treatment group are shown in Table 2 . In patients who underwent treatment intensification with a GLP-1 RA, a trend towards decreased rates of overall hypoglycaemia and outpatient hypoglycaemia was seen from baseline to follow-up. Conversely, for patients in the no intensification group, there was a trend towards increased rates of overall hypoglycaemia and outpatient hypoglycaemia from baseline to follow-up. 
| Change in semi-annual healthcare costs
The change in LS means semi-annual total healthcare costs over time, according to treatment group, is shown in Figure 4 . From baseline to follow-up, the increase in LS mean semi-annual total healthcare costs was significantly greater in the no intensification group (+5260 USD; from 6926 USD to 12 192 USD) compared with the early intensification group (-560 USD; from 9581 USD to 9021 USD; P = .0011) and the delayed intensification group (+1943 USD; from 7780 USD to 9723 USD; P = .001).
| Factors associated with treatment intensification with a GLP-1 RA
We investigated baseline factors (ascertained from the 6-month period immediately prior to basal insulin initiation) that were associated with treatment intensification with a GLP-1 RA. 
| DISCUSSION
In patients with T2D who do not meet glycaemic goals, the importance of timely treatment intensification, when appropriate, has been emphasized by international clinical guidelines. Despite this, clinical inertia remains a major barrier to optimal diabetes care, contributing to poor outcomes and increased healthcare costs.
Using data from a large administrative claims database, representative of a large proportion of the US population, this study revealed that only 9.0% of patients who failed to meet HbA1c targets using inclusion of antidiabetes treatments other than GLP-1 RA, as well as treatments for diabetes complications and comorbidities, in the total prescription drug costs of the no intensification group. Interestingly, in the early intensification vs delayed intensification comparison, higher comorbidities were found to be associated with earlier intensification, whereas, in the intensification vs no intensification comparison, higher comorbidities were associated with no intensification.
Results of the subgroup analysis of patients with HbA1c ≥ 8.0%
were largely comparable to those obtained for the overall patient population with HbA1c ≥ 7.0%, with similar baseline characteristics and trends among the 3 groups. The differences in HbA1c reduction and rate of hypoglycaemic events between the groups who received early and delayed intensification with a GLP-1 RA were less evident in the subgroup analysis, compared with results from the overall patient population; however, a similar trend was observed in change in semi-annual healthcare costs among the 3 groups over time.
A major strength of this study is the use of data from clinical practice rather than from the controlled environment of a clinical trial, allowing for assessment of real-world practices and outcomes.
Included patients were identified from a large health insurance claims database representative of a large proportion of the US population, and both descriptive and adjusted results were presented.
As with all studies, our analysis has certain limitations. As this retrospective study used data derived from a pre-existing database, only captured information was analysed. Consequently, the study Finally, for patients with T2D who are inadequately controlled with basal insulin, timely treatment intensification with a GLP-1 RA was associated with better glycaemic control and lower financial burden than that observed with delayed treatment intensification.
